Science and Research

Benidipine calcium channel blocker promotes the death of cigarette smoke-induced senescent cells and improves lung emphysema

Smoking is the main risk factor for many lung diseases including chronic obstructive pulmonary disease. Cigarette smoke (CS) contains carcinogenic and reactive oxygen species that favor DNA mutations and perturb the homeostasis and environment of cells. CS induces lung cell senescence resulting in a stable proliferation arrest and a senescence-associated secretory phenotype. It was recently reported that senescent cell accumulation promotes several lung diseases. In this study, we performed a chemical screen, using an FDA-approved drug library, to identify compounds selectively promoting the death of CS-induced senescent lung cells. Aside from the well-known senolytic, ABT-263, we identified other potentially new senescence-eliminating compounds, including a new class of molecules, the dihydropyridine family of calcium voltage-gated channel (CaV) blockers. Among these blockers, Benidipine, decreased senescent lung cells and ameliorates lung emphysema in a mouse model. The dihydropyridine family of CaV blockers thus constitutes a new class of senolytics that could improve lung diseases. Hence, our work paves the way for further studies on the senolytic activity of CaV blockers in different senescence contexts and age-related diseases.

  • Palazzo, A.
  • Makulyte, G.
  • Goerhig, D.
  • Médard, J. J.
  • Gros, V.
  • Trottein, F.
  • Adnot, S.
  • Vindrieux, D.
  • Flaman, J. M.
  • Bernard, D.

Keywords

  • Mice
  • Animals
  • Calcium Channel Blockers/pharmacology/therapeutic use
  • *Cigarette Smoking/adverse effects
  • *Pulmonary Emphysema/genetics
  • Lung/metabolism
  • *Dihydropyridines/pharmacology/therapeutic use/metabolism
  • *Emphysema/metabolism
  • Cellular Senescence
  • calcium channel
  • cigarette smoke
  • lung disease
  • senolytic
Publication details
DOI: 10.18632/aging.205259
Journal: Aging (Albany NY)
Pages: 13581-13592 
Number: 23
Work Type: Original
Location: UGMLC
Disease Area: COPD
Partner / Member: JLU
Access-Number: 38095616

DZL Engagements

chevron-down